Louis Gerard

Do tell me how this is good for consumers $FLYYQ #spiritairlines

Remember when the JetBlue $JBLU Spirit merger was blocked for antitrust reasons? Guess it was the wrong call.

Bank results are in: JPMorgan $JPM: $5.94 EPS, beat. Citi $C: $3.06 vs $2.64 expected, crushed it. Wells Fargo $WFC: missed. Two out of three mega banks posted blowout quarters during a tumultuous period. Long

@FluentInQuality That’s when you need to buy

I'm really seeing everyone switching sides on $NVO. A couple of months ago, it was loved. Now, not so much anymore.

@investseekers Did the same yesterday, same sentiment

Added to $NVO today. The past 1.5 years have not been great as a shareholder, but sentiment now feels extremely negative . The company just delivered what may be the most successful pharma launch ever with oral Wegovy, with EU rollout expected later this year, yet the stock is still priced as a diabetes business without an obesity portfolio. I do not expect a quick rebound, but I am very comfortable buying at these levels. #stocks #InvestingTips

Even a modest re-rating to 12x forward P/E on normalized earnings gets you to $38, a 38% upside from here. Yes, China risk is real. Yes, food delivery could stay unprofitable longer. But at 8x earnings with a 10% capital return yield and a core business that's actually improving, the risk/reward is heavily skewed. Full model and thesis breakdown here: seekingalpha.com/article/488617…

The valuation gap is absurd: — $JD: ~8x trailing P/E, 0.18x EV/Sales — Alibaba: 18x P/E, 1.8x EV/Sales — PDD: 11x P/E, 2.8x EV/Sales — Coupang: 83x P/E, 1.0x EV/Sales And JD returned ~10% of its market cap to shareholders in 2025 alone — $3B in buybacks + $1.4B in dividends. That's not a company in distress. That's a company buying itself back while Wall Street isn't looking.

JD.com $JD at 8x earnings is China's most misunderstood stock. The market sees a money-losing e-commerce company. What it's actually looking at is a profitable retail machine deliberately burning cash to build a food delivery army and invade Amazon's backyard. Strip out the new businesses, and this is one of the cheapest quality compounders in global e-commerce. (1/4)

@TheLongInvest Didn’t know that anyone cared about $ARK anymore

$ARK are selling out heavy!!

More so on Novo Nordisk's $NVO AGM, I want to dive into the newly elected directors: Jan van de Winkel — Co-founder and CEO of Genmab, Europe's largest biotech. Built it from a 20-person startup to 8 approved antibody therapies including DARZALEX. 30+ years in therapeutic antibodies, 300+ scientific publications, 150+ patents. This is one of the most successful biotech founders in European history, joining the board. Ramona Sequeira — 30 years in global pharma. Led Takeda's US business through a 3x revenue expansion and was the first woman to chair PhRMA's board. Before that, 20 years at Eli Lilly launching brands across the US and Europe. She knows exactly how to compete in the market Novo is losing ground in. Helena Saxon — Former CFO of Investor AB (the Wallenberg family's holding company), Goldman Sachs alumna, and 14 years on the board of rare disease specialist Sobi. Deep capital markets and healthcare investing expertise. The message is clear: the Foundation, which controls the company, saw a business drifting and intervened with force. The new board has biotech R&D depth, global commercial execution experience, and financial discipline, exactly what Novo needs to fight back against Lilly. At 10x earnings, you're getting a turnaround with A-list governance for free.

AGM confirms that $NVO is still the best opportunity in the pharmaceutical segment.

started buying $JD, similar setup to $BABA back in the days.

+6% today

Considering the current situation in Iran, I don't believe that Dubai is over. The charts showcasing the property crash are an opportunity! Just bought $EMAAR at ~12 AED. The math is simple: → Record FY2025: revenue +40%, EBITDA +33%, net profit +36% → AED 155bn backlog = 3+ years of revenue locked in → Trading at 5.9x earnings. Peer avg is 6.6x. Industry is 14.8x. → 8.5% dividend yield while you wait The market is pricing in a Dubai crash that S&P, UBS, and every major agency says probably isn't coming. Fortress balance sheet, 10.7% debt-to-equity, $11.7bn in escrow. The risk is real, 100K+ units hitting Dubai in 2026 vs 27K avg. But at sub-6x earnings with this backlog, you're being paid to take that risk.

Pfizer $PFE at 8x earnings is being priced like a company that's already dead. The market has completely written off the turnaround. That's exactly why I'm pounding the table as behind the noise: — BRAFTOVI just got full FDA approval as the only drug for first-line BRAF V600E colorectal cancer, doubling median survival to 30 months — Atimociclib showed a 40% reduction in disease progression for second-line breast cancer a notoriously hard-to-treat setting — The obesity candidate PF-08653994 hit 12.3% weight loss at 28 weeks with no plateau, potentially rivaling the 20%+ benchmarks — 10 Phase 3 trials launching for the obesity asset alone — FCF yield of 5.9%, dividend yield of 6.38% Even a modest re-rating to 12x forward P/E gets you to $35 — a 40%+ upside from here. Yes, the $17-18B patent cliff is real. But the market is pricing in zero credit for the Seagen oncology portfolio, zero for obesity, and zero for execution on cost cuts. At 8x earnings, you're being paid to wait. Full thesis here: seekingalpha.com/article/488561…

Long $GRAB More here: seekingalpha.com/article/486944…

"But Lilly is winning the GLP-1 war." Lilly $LLY trades at ~30x forward earnings. Novo trades at ~11x forward. That gap implies Novo $NVO is a dying business, but it just got Wegovy HD approved last week and its oral Wegovy hit 50k weekly scripts in under three weeks. This is a $160B market cap company being priced like it has no future, while operating in a TAM heading to $100B+ by 2030. I'm buying hand over fist. (3/3)

The bear thesis for $NVO makes sense until you dive into the numbers — Trailing P/E of ~10x, versus a 10-year average of ~21x and pharma peer average of 18x — ROE of 60%, ROIC above 40% — $48.5B in TTM revenue, still the dominant GLP-1 franchise globally — FDA warning letter is about reporting procedures, not drug safety — the FDA explicitly said it does not mean semaglutide caused the adverse events — Indian generics are 5+ years from branded patent expiry (2/3)

Novo Nordisk $NVO at 10x earnings is the most obvious buy on the market, and the Street is too scared to touch it. The stock is down 74% from its 2024 high while Bernstein just initiated with an Underperform. Sentiment is at rock bottom. That's exactly when you want to be paying attention. (1/3)

@firesale_ae Do you think that it is a deal breaker compared to EMAAR's current valuation

@PermiatCap the 100k units number is the real wildcard. we're tracking the supply data by area and some neighbourhoods are looking at 3-4x their current inventory landing in the next 18 months. that's where the pressure shows up first, not citywide averages